Key Points
• In this unusual case, a 42-year-old woman presented with general malaise and anorexia for the past 3 months. The initial evaluation indicated advanced right upper lung cancer with multiple brain and bone metastases. Staging was T1bN3M1b, stage 4B. Her labs indicated disseminated intravascular coagulation (DIC) induced by advanced...
Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33854939/
doi: 10.1016/j.rmcr.2021.101393. 1 Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, Japan. 2 Department of Respiratory Medicine, Ijinkai Takeda General...
-
NSCLC Connect5yrKey Points • In this unusual case, a 42-year-old woman presented with general malaise and anorexia for the past 3 months. The initial evaluation indicated advanced right upper lung cancer with multiple Show More
Utility of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients with Non-small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33878340/
Although ctDNA exhibited similar utility to tissue biopsies, more mutations in targetable genes were missed in tissue biopsies. Therefore, the evaluation of ctDNA in conjunction with tissue biopsies may help...
-
NSCLC Connect5yrKey Points • In this retrospective study, researchers compared the utility of circulating tumor DNA (ctDNA) and solid tumor biopsy in non-small cell lung cancer. They assessed the usefulness of ctDNA in Show More
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33875457/
The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular...
Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC
In the Spanish phase II NADIM trial reported in The Lancet Oncology , Provencio et al found that the addition of nivolumab to neoadjuvant chemotherapy and the use of adjuvant...
Key Points
• In this retrospective study, researchers assessed how allelic frequency relates to survival in patients with EGFR mutant non-small cell lung cancer (NSCLC). The investigators conflated allelic frequency and the presence of co-mutations, which is an established negative predictive factor for targeted therapy.
• The researchers...
The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33869038/
EGFR mutations represent the most common currently targetable oncogenic driver in non-small cell lung cancer. There has been tremendous progress in targeting this alteration over the course of the last...